| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net loss | ||||||
-34,470 | -17,251 | - | - | - | - | - |
Net loss | ||||||
- | - | -12,695 | -11,587 | -9,461 | -8,473 | -9,804 |
Adjustments to reconcile net loss to cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
54 | 12 | - | - | - | - | - |
Gain on disposal of equipment | ||||||
0 | 0 | - | - | - | - | - |
Equity based compensation | ||||||
15,177 | 6,600 | 4,749 | 5,999 | 7,968 | 5,743 | 3,305 |
Fair value of subsidiary stock issued to acquire research and development from Trek Therapeutics, PBC | ||||||
3,162 | 0 | 543 | 0 | 0 | - | 837 |
Depreciation | ||||||
- | - | 11 | 10 | 10 | 15 | 17 |
Change in fair value of modified options | ||||||
666 | 0 | - | - | 0 | - | 1,074 |
Changes in operating assets and liabilities: | ||||||
Inventory | ||||||
577 | 0 | - | - | - | - | - |
Vendor deposits | ||||||
-100 | 0 | - | - | - | - | - |
Prepaid expenses | ||||||
90 | 61 | -17 | 102 | -44 | -8 | -20 |
Payment of long term deposit | ||||||
-47 | -37 | 10 | 0 | - | - | - |
Security deposit | ||||||
- | - | - | - | 0 | - | - |
Accounts payable | ||||||
537 | 478 | 102 | 149 | -333 | -110 | 349 |
Lease liability, net | ||||||
5 | 0 | - | - | - | - | - |
Amortization of debt discount | ||||||
- | - | 3 | 0 | 585 | 593 | 2,441 |
Lease liability, net | ||||||
- | - | 210 | -422 | 3,113 | 0 | - |
Stock based payable | ||||||
- | - | - | - | -226 | 226 | 0 |
Deferred rent payable | ||||||
0 | -2 | 2 | 0 | -3 | 1 | 3 |
Net cash used in operating activities | ||||||
-15,482 | -10,255 | -7,470 | -5,107 | -4,523 | -1,997 | -1,762 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Proceeds from disposal of equipment | ||||||
2 | 0 | - | - | - | - | - |
Payments of patent costs | ||||||
111 | 268 | 0 | - | - | - | - |
Payment of trademark costs | ||||||
0 | 0 | 0 | - | - | - | - |
Purchase of property and equipment | ||||||
177 | 38 | 9 | 16 | 15 | 3 | 11 |
Payment of long term deposit | ||||||
- | - | - | - | 2 | 0 | - |
Net cash used in investing activity | ||||||
-285 | -307 | -9 | -16 | -18 | -3 | -11 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Net proceeds from the sale of Series C preferred stock and warrants | ||||||
- | - | - | - | - | - | 1,768 |
Proceeds from sale of common stock | ||||||
10,007 | 9,139 | 6,011 | 5,226 | 4,759 | 1,969 | 299 |
Proceeds from sale of subsidiary stock to non-controlling interest | ||||||
5,011 | 0 | - | - | - | - | - |
Proceeds from sale of Series E preferred stock | ||||||
0 | 1,492 | 29 | 0 | - | - | - |
Proceeds from sale of Series D preferred stock | ||||||
- | - | 1,929 | - | 450 | 0 | - |
Proceeds from sale of Series E preferred stock | ||||||
- | - | 0 | - | - | - | - |
Proceeds from exercise of warrants | ||||||
7,470 | 2,217 | 0 | - | 24 | 0 | - |
Proceeds from exercise of options | ||||||
938 | 615 | 0 | - | 20 | 0 | - |
Proceeds from common stock subscription | ||||||
- | - | - | - | 0 | - | - |
Payments of related party notes | ||||||
- | - | - | - | - | - | 30 |
Net repayments of related party advances | ||||||
- | - | - | - | - | -30 | 13 |
Net cash provided by financing activities | ||||||
23,427 | 13,465 | 7,971 | 5,226 | 5,255 | 1,938 | 2,052 |
Net increase in cash and cash equivalents | ||||||
7,658 | 2,902 | - | - | - | - | - |
Net increase in cash and cash equivalents | ||||||
- | - | 491 | 102 | 713 | -62 | 277 |
Supplemental disclosures of cash flow information: | ||||||
Cash paid during the period for interest | ||||||
0 | 0 | - | - | - | - | - |
Cash paid during the period for interest | ||||||
- | - | - | 0 | - | 11 | 0 |
Cash paid during the period for income taxes | ||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 |
Noncash investing and financing activities: | ||||||
Reclassify derivative liability to equity | ||||||
- | 3,044 | - | 103 | - | - | - |
Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock | ||||||
- | - | - | 0 | - | - | - |
Dividend payable on preferred stock charged to additional paid in capital | ||||||
25 | 884 | - | 0 | - | - | - |
Convertible bridge notes payable exchanged for preferred shares | ||||||
- | - | - | - | - | - | 600 |
Right-to-use assets and lease liability recorded upon adoption of ASC 842 | ||||||
422 | 0 | 0 | - | 1 | 87 | 0 |
Record right-to-use assets and related lease liability | ||||||
511 | 0 | - | - | - | - | - |
Series C Preferred Stock [Member] | ||||||
Common stock issued upon conversion preferred stock and accrued dividends | ||||||
399 | 744 | 116 | - | - | - | - |
Series D Preferred Stock [Member] | ||||||
Common stock issued upon conversion preferred stock and accrued dividends | ||||||
0 | 540 | 0 | - | - | - | - |
Series E Preferred Stock [Member] | ||||||
Common stock issued upon conversion preferred stock and accrued dividends | ||||||
0 | 315 | 0 | - | - | - | - |
Embedded Derivative Financial Instruments, Upon Issuance of Series D Preferred Stock [Member] | ||||||
Reclassify derivative liability to equity | ||||||
- | - | 1,049 | - | - | - | - |
Embedded Derivative Financial Instruments [Member] | ||||||
Reclassify derivative liability to equity | ||||||
- | - | 20 | - | - | - | - |
Upon Adoption of ASU 2017-11 [Member] | ||||||
Reclassify derivative liability to equity | ||||||
0 | 3,044 | 0 | - | - | - | - |